Quest Diagnostics Proxy Statement Filed
Ticker: DGX · Form: DEF 14A · Filed: 2025-04-04T00:00:00.000Z
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting, auditor
Related Tickers: DGX
TL;DR
Quest Proxy filed: vote on directors & auditors for 2025.
AI Summary
Quest Diagnostics Inc. filed its definitive proxy statement on April 4, 2025, for its annual meeting on May 15, 2025. The filing outlines the company's governance, executive compensation, and proposals to be voted on by shareholders. Key areas include the election of directors and the ratification of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025.
Why It Matters
This filing provides shareholders with crucial information to make informed voting decisions on company leadership and financial oversight, impacting the company's strategic direction and shareholder value.
Risk Assessment
Risk Level: low — This is a routine annual filing providing information to shareholders and does not indicate any immediate financial distress or significant operational changes.
Key Players & Entities
- Quest Diagnostics Inc. (company) — Registrant
- PricewaterhouseCoopers LLP (company) — Proposed independent auditor
- April 4, 2025 (date) — Filing date
- May 15, 2025 (date) — Annual meeting date
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information for the annual meeting, including details on director nominations, executive compensation, and proposals for shareholder votes, such as ratifying the independent auditor.
When is the annual meeting of shareholders scheduled?
The annual meeting of shareholders is scheduled for May 15, 2025.
Who is proposed to be Quest Diagnostics' independent registered public accounting firm for the upcoming fiscal year?
PricewaterhouseCoopers LLP is proposed to be ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
What is the filing date of this proxy statement?
This definitive proxy statement was filed on April 4, 2025.
What is the company's fiscal year end?
Quest Diagnostics' fiscal year ends on December 31.
From the Filing
0000930413-25-001171.txt : 20250404 0000930413-25-001171.hdr.sgml : 20250404 20250404163703 ACCESSION NUMBER: 0000930413-25-001171 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 50 CONFORMED PERIOD OF REPORT: 20250515 FILED AS OF DATE: 20250404 DATE AS OF CHANGE: 20250404 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC CENTRAL INDEX KEY: 0001022079 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 161387862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-12215 FILM NUMBER: 25815443 BUSINESS ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 BUSINESS PHONE: 9735202700 MAIL ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 FORMER COMPANY: FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC DATE OF NAME CHANGE: 19960903 DEF 14A 1 c111937_def14a-ixbrl.htm   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 14A   Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )   Filed by the Registrant [X] Filed by a Party other than the Registrant [_]   Check the appropriate box:   [_] Preliminary Proxy Statement [_] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (as permitted by Rule 14a-6(e)(2)) [X] Definitive Proxy Statement [_] Definitive Additional Materials [_] Soliciting Material Pursuant to Section 240.14a-12   Quest Diagnostics Incorporated   (Name of Registrant as Specified In Its Charter)   (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)   Payment of Filing Fee (Check the appropriate box):   [X] No fee required [_] Fee paid previously with preliminary materials [_] Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11     Notice of 2025 Annual Meeting of Stockholders   and   Proxy Statement   April 4, 2025     The Quest Way       Purpose Why we exist   Working together to create a healthier world, one life at a time                 We help people make the best decisions to improve health by providing high-quality, innovative, convenient and affordable diagnostic testing insights and services using our scale and extensive reach   Strategy How we grow   ● Collaborating with healthcare providers and partners to leverage our broad access     ● Offering an industry-leading menu of testing and other services     ● Leveraging our data assets and services to improve population health and enable value-based care       ● Continuously improving our quality and efficiency by leveraging the Quest Management System and by embracing innovative technologies, such as automation and artificial intelligence (“AI”)       Who we serve: physicians, hospitals, patients and consumers, health plans, employers, emerging retail healthcare providers, government agencies, pharmaceutical companies and other commercial clinical laboratories                   Culture How we work   Customer first, Care, Collaboration, Continuous improvement, Curiosity             Notice of 2025 Annual Meeting of Stockholders Quest Diagnostics Incorporated One Insights Drive Clifton, New Jersey May 15, 2025, 10:30 a.m. Eastern Time   April 4, 2025   Dear Fellow Stockholder:   It is my pleasure to invite you to attend Quest Diagnostics’ 2025 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, stockholders will vote on the following, in addition to any other business as may properly come before the Annual Meeting or any adjournme